Corcept Therapeutics
CORT
429 hedge funds and large institutions have $6.41B invested in Corcept Therapeutics in 2025 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 146 increasing their positions, 156 reducing their positions, and 50 closing their positions.
24% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 50
19% more call options, than puts
Call options by funds: $74.4M | Put options by funds: $62.4M
9% more capital invested
Capital invested by funds: $5.87B → $6.41B (+$538M)
2% more funds holding
Funds holding: 422 → 429 (+7)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less repeat investments, than reductions
Existing positions increased: 146 | Existing positions reduced: 156
1.27% less ownership
Funds ownership: 74.52% → 73.25% (-1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$92.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$61.1M |
| 3 |
JP Morgan Chase
New York
|
+$42.5M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$32.1M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$27.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$39.2M |
| 2 |
BlackRock
New York
|
-$34.9M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$32.7M |
| 4 |
Morgan Stanley
New York
|
-$30.9M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$30.4M |
CORT Hedge Fund Activity: Q3 2025 in Review
429 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2025, worth a combined $6.41B — up 9.2% from $5.87B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new CORT positions and 50 closed out — a net gain of 12 holders — while 146 added to existing stakes and 156 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $92.2M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $39.2M.
- 429 institutional investors held Corcept Therapeutics (CORT) as of Q3 2025, up from 422 in Q2 2025.
- Funds reported $6.41B of Corcept Therapeutics stock for Q3 2025, up 9.2% quarter-over-quarter.
- 62 funds opened new Corcept Therapeutics positions in Q3 2025 and 50 closed out, a net change of +12 holders.
- The largest Corcept Therapeutics buyer in Q3 2025 was AQR Capital Management, an estimated $92.2M added.
- The largest Corcept Therapeutics seller in Q3 2025 was T. Rowe Price Investment Management, an estimated $39.2M sold.
Based on aggregated 13F filings for Q3 2025.